【摘要】 第1代表皮生长因子受体酪氨酸激酶抑制药(EGFR-TKIs)吉非替尼、厄洛替尼和埃克替尼基于其靶点作用的优势，目前在临床上广泛用于EGFR突变的晚期或转移性非小细胞肺癌(NSCLC)的一线治疗。但在临床应用中，不同患者在使用标准剂量的第1代EGFR-TKIs后的疗效和药物不良反应不尽相同，这可能与个体差异有关。基于此，本文对第1代EGFR-TKIs的药代动力学参数、治疗药物监测(TDM)以及代谢酶和转运体基因多态性现有研究进行综述，为促进其临床个体化用药和肿瘤精准治疗提供参考。更多还原

【Abstract】 Gefitinib, erlotinib and icotinib are the first-generation epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs), which are widely used in the first-line treatment of advanced or metastatic non-small cell lung cancer(NSCLC) with EGFR mutation based on the advantages of their target action. However, in clinical application, the efficacy and toxic reactions vary among patients after using first-generation EGFR-TKIs with standard dose, which may be related to individual differences. Based on this, this paper reviewed the existing studies on pharmacokinetic parameters, therapeutic drug monitoring(TDM), and gene polymorphism of metabolic enzymes and transporters of first-generation EGFR-TKIs, in order to provide reference for promoting its clinical individualized medication and precision treatment of tumors.更多还原